Merus N.V. MRUS · Stock Open Merus N.V. in new tab
Merus N.V. Analysis (MRUS)
Is Merus N.V. a good investment? Merus N.V. (MRUS) is currently trading at 90.00 USD.
Investor FAQ
Does Merus N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Merus N.V.?
Merus N.V. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Community Discussion